H.C. Wainwright analyst Mitchell Kapoor initiated coverage of MeiraGTx (MGTX) with a Buy rating and $20 price target The firm has conviction that AAV-AQP1 for radiation-induced xerostomia is one of the most “risk-mitigated late-stage gene therapy programs in development.” It recommends buying the shares ahead of the pivotal data in late 2026 or early 2027.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX: